JelikaLite Corp announced today positive results from a study funded by the NSF SBIR Phase I grant. This study demonstrated that tPBM is a potentially effective treatment modality for improving symptoms of autism in children. Open Label Study had 25 participants.
As a result of the treatment, children’s behavior and communication skills improved – as measured by CARS (Childhood Autism Rating Scale) and observations by an independent SLP. The EEG data revealed redistribution of brainwaves from slowest (delta) to fastest (gamma), suggesting that Near InfraRed light may modulate brain tissue. Additional studies are being planned to further elucidate this mechanism and other efficacious effects of the technology platform.
In addition, the company has announced a successful raise if $760k. Investors included NY Ventures and Brain Foundation / BioVerge SPV, through which many angel investors participated.
Furthermore, JelikaLite has been accepted to Elementa Labs, the virtual incubator program of the Mount Sinai Health System in New York, NY, as a member of its 2023 cohort.
“The JelikaLite team is excited to start Elementa Labs, as it is a significant milestone for the company. The program will provide guidance for potential commercialization of our technology in the US. The news is especially encouraging as the company has just completed its 2 clinical studies with positive results,” noted Katya Sverdlov, CEO at JelikaLite.
